These findings position CCL3 as a downstream effector of TACC2-mediated immune activation, highlighting its possible relevance in augmenting anti-tumor immunity and the effectiveness of immunotherapy in mesenchymal tumors. The gene discussed is TACC2; the disease is neoplasm.